Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size
2179 studies found for:    Open Studies | "Breast Neoplasms"

Modify this search | How to Use Search Results

Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Cancel
Rank Status Study
1 Recruiting Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors
Conditions: Breast Neoplasms;   Breast Cancer;   Breast Carcinoma;   Malignant Neoplasm of Breast;   Cancer of Breast;   Mammary Neoplasm, Human;   Human Mammary Carcinoma;   Malignant Tumor of Breast;   Mammary Cancer;   Mammary Carcinoma;   Anxiety;   Fear;   Neoplasm Remission, Spontaneous;   Spontaneous Neoplasm Regression;   Regression, Spontaneous Neoplasm;   Remission, Spontaneous Neoplasm;   Spontaneous Neoplasm Remission
Interventions: Behavioral: Acceptance and Commitment Therapy;   Behavioral: Survivorship Education;   Behavioral: Usual Care
2 Recruiting A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer
Conditions: Cancer of the Breast;   Breast Cancer;   Advanced Breast Cancer;   Metastatic Breast Cancer;   Male Breast Cancer;   Triple Negative Breast Cancer;   ER+ Breast Cancer
Interventions: Drug: Female AR(+) TNBC Enzalutamide Naïve;   Drug: Female AR(+) TNBC Enzalutamide Treated;   Drug: Female ER(+) BC Patients;   Drug: Male ER(+) BC Patients
3 Not yet recruiting A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Neoplasm;   Triple-Negative Breast Cancer;   Triple Negative Breast Cancer;   ER-Negative PR-Negative HER2-Negative Breast Neoplasms;   ER-Negative PR-Negative HER2-Negative Breast Cancer
Interventions: Biological: Bavituximab;   Drug: Taxane
4 Recruiting Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
5 Recruiting Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer Patients Who Have Failed an Anthracycline (CAT)
Conditions: Breast Neoplasms;   Breast Cancer
Interventions: Drug: Taxane;   Drug: Taxotere;   Drug: Abraxane;   Drug: Ixabepilone
6 Recruiting Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Malignant Tumor of the Breast
Interventions: Drug: Trastuzumab;   Drug: Pertuzumab;   Drug: Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine
7 Not yet recruiting Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Conditions: Breast Cancer;   Ductal Carcinoma;   Invasive Breast Carcinoma;   Invasive Ductal Breast Carcinoma
Interventions: Biological: Talimogene laherparepvec;   Drug: Paclitaxel
8 Not yet recruiting A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
Conditions: Breast Cancer;   Estrogen Receptor Positive Breast Cancer;   Node-negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Other: Breast Cancer Treatment Decision Aid for women 70+;   Other: Usual Care
9 Recruiting Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
Conditions: Breast Cancer;   Node-positive Breast Cancer;   Breast Adenocarcinoma;   Invasive Breast Carcinoma;   Lobular Breast Carcinoma In Situ
Interventions: Radiation: External Beam Radiation Therapy;   Other: Questionnaire Administration;   Other: Laboratory Biomarker Analysis
10 Recruiting Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Conditions: Metastatic Breast Cancer;   Breast Carcinoma;   HER-2 Positive Breast Cancer
Interventions: Drug: Ruxolitinib;   Drug: Trastuzumab
11 Recruiting Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Conditions: Breast Neoplasms;   Triple Negative Breast Neoplasms
Interventions: Drug: Dasatinib;   Procedure: Conventional Surgery;   Other: Laboratory Biomarker Analysis
12 Recruiting Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
Conditions: Breast Cancer;   Breast Carcinoma;   Breast Tumors;   Malignant Neoplasm of Breast
Interventions: Drug: Paclitaxel;   Drug: Alisertib
13 Recruiting Bright Light on Fatigue in Women Being Treated for Breast Cancer
Conditions: Breast Neoplasms;   Breast Cancer;   Cancer of Breast;   Cancer of the Breast
Interventions: Other: Bright blue-green light using light visor cap;   Other: Dim red light using light visor cap;   Other: European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire;   Other: Epworth Sleepiness Scale;   Other: Pittsburgh Sleep Quality Index;   Other: Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance;   Other: Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue;   Device: Digital foot candle datalogging light meter (Extech Instrument, Model SDL400);   Device: Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA);   Other: Horne-Ostberg Morningness-Eveningness Questionnaire;   Other: Daily Fatigue and Sleep Log
14 Recruiting Proton Radiation for Stage II/III Breast Cancer
Conditions: Breast Cancer;   Breast Neoplasm;   Breast Tumor;   Cancer of the Breast
Intervention: Radiation: Proton Radiotherapy
15 Recruiting Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer
Conditions: Ductal Breast Carcinoma in Situ;   Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Invasive Ductal Breast Carcinoma With Predominant Intraductal Component;   Lobular Breast Carcinoma in Situ;   Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate;   Mucinous Ductal Breast Carcinoma;   Papillary Ductal Breast Carcinoma;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Tubular Ductal Breast Carcinoma
Interventions: Radiation: accelerated partial breast irradiation;   Radiation: intensity-modulated radiation therapy;   Radiation: image-guided radiation therapy;   Procedure: therapeutic conventional surgery;   Other: questionnaire administration;   Other: laboratory biomarker analysis
16 Not yet recruiting Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Conditions: Breast Cancer;   Cancer of Breast;   Breast Neoplasms;   Cancer of the Breast
Interventions: Device: Oncotype DX® Breast Cancer Assay;   Behavioral: FACT-B;   Drug: Goserelin;   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Tamoxifen
17 Recruiting Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
Conditions: Breast Cancer;   Metastatic Breast Cancer;   Recurrent Breast Cancer
Interventions: Drug: Pemetrexed;   Drug: Sorafenib
18 Recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
19 Recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
20 Not yet recruiting Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients
Conditions: Breast Cancer;   Malignant Neoplasm of Breast
Interventions: Procedure: Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI);   Procedure: Tc99m Sestamibi Molecular Breast Imaging (MBI);   Drug: 99mTc Sestamibi
To Top

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
† Indicates status has not been verified in more than two years